A vaccine for tularaemia

Expert Opinion on Biological Therapy

Volumn 3, Issue 4, 2003, Pages 645-653

  Titball, R W ^a   Oyston, P C F ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Francisella tularensis; Tularaemia; Vaccine

Indexed keywords

LIVE VACCINE; PROTEIN SUBUNIT; TULAREMIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ATTENUATION; BACTERIAL GROWTH; BACTERIUM CULTURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; FATALITY; FRANCISELLA TULARENSIS; INFECTION RISK; LICENSING; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; REVIEW; STRAIN IDENTIFICATION; SYMPTOMATOLOGY; TULAREMIA; VACCINATION;

ANIMALS; BACTERIAL VACCINES; FRANCISELLA TULARENSIS; HUMANS; MUTATION; TULAREMIA; VACCINES, ATTENUATED;

ANIMALIA; BACTERIA (MICROORGANISMS); FRANCISELLA TULARENSIS;

EID: 0037926887     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.4.645     Document Type: Review

References (101)

1. MCCOY GW, CHAPIN CW: Further observations on a plague-like disease of rodents with a preliminary note on the causative agent, Bacterium tularense. J. Infect. Dis. (1912) 10:61-72.
2. MORNER T: The ecology of tularemia. Rev. Sci. Tech. Off. Int. Epiz. (1992) 11:1123-1130.
3. BERDAL BP, MEHL R, MEIDELL NK, LORENTZEN-STYR A-M, SCHEEL O: Field investigations of tularemia in Norway. FEMS Immunol. Med. Microbiol. (1996) 13:191-195.
4. BOYCE JM: Recent trends in the epidemiology of tularemia in the United States. J. Infect. Dis. (1975) 131:197-199.
5. OHARA Y, SATO T, FUJITA H, UENO T, HOMMA M: Clinical manifestations of tularemia in Japan - analysis of 1355 cases observed between 1924 and 1987. Infection (1991) 19:14-17.
6. STEWART SJ: Tularemia: association with hunting and farming. FEMS Immunol. Med. Microbiol. (1996) 13:197-199.
7. TARNVIK A, SANDSTROM G, SJOSTEDT A: Epidemiological analysis of tularemia in Sweden 1931-1993. FEMS Immunol. Med. Microbiol. (1996) 13:201-204.
8. DOROFE'EV KA: Classification of the causative agent of tularemia. Symp. Res. Works Inst. Epidemiol. Mikrobiol. Chita. (1947) 1:170-180.
9. OLSUFJEV NG, EMELYANOVA OS, DUNAEVA TN: Comparative study of strains of B. tularense in the Old and New World and their taxonomy. J. Hyg. Epidemiol. Microbiol. Immunol. (1959) 3:138-149.
10. SJOSTEDT A: Family XVII. Francisellaceae, Genus I. Francisella. In: Bergey's Manual of Sytematic Bacteriology. Brenner DJ (Ed.), Springer-Verlag, Berlin (2002).
11. EIGELSBACH HT, MCGANN VG: Genus Francisella Dorofe'ev 1947. In: Bergey's Manual of Systematic Bacteriology. Kreig NR, Holt JG (Eds), Williams & Wilkins Co., Baltimore, MD (1984):394-399.
12. OLSUFJEV NG, MESHCHERYAKOVA IS: Subspecific taxonomy of Francisella tularensis McCoy and Chapin 1912. Int. J. System. Bacteriol. (1983) 33:872-874.
13. FORSMAN M, SANDSTROM G, SJOSTEDT A: Analysis of 16S ribosomal DNA sequences of Francisella strains and utilization for determination of the phylogeny of the genus and for identification of strains by PCR. Int. J. System. Bacteriol. (1994) 44:38-46.
14. HOLLIS DG, WEAVER RE, STEIGERWALT AG et al.: Francisella philomiragia comb. nov. (formerly Yersinia philomiragia) and Francisella tularensis biogroup novicida (formerly Francisella novicida) associated with human disease. J. Clin. Microbiol. (1989) 27:1601-1608.
15. OHARA Y, SATO T, HOMMA M: Arthropod-borne tularemia in Japan: clinical analysis of 1,374 cases observed between 1924 and 1996. J. Med. Entomol. (1998) 35:471-473.
16. TARNVIK A, ERICSSON M, GOLOVLIOV I, SANDSTROM G, SJOSTEDT A: Orchestration of the protective immune response to intracellular bacteria: Francisella tularensis as a model organism. FEMS Immunol. Med. Microbiol. (1996) 13:221-225.
17. EVANS ME, GREGORY DW, SCHAFFNER W, MCGEE ZA: Tularemia - a 30-year experience with 88 cases. Medicine (1985) 64:251-269.
18. GILL V, CUNHA BA: Tularemia pneumonia. Semin. Respir. Infect. (1997) 12:61-67.
19. MCCRUMB FR: Aerosol infection of man with Pasteurella tularensis. Bacteriol. Rev. (1961) 25:262-267.
20. BURKE DS: Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J. Infect. Dis. (1977) 135:55-60.
21. ENDERLIN G, MORALES L, JACOBS RF, CROSS JT: Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin. Infect. Dis. (1994) 19:42-47.
22. JOHANSSON A, BERGLUND L, SJOSTEDT A, TARNVIK A: Ciprofloxacin for treatment of tularemia. Clin. Infect. Dis. (2001) 33:267-268.
23. DENNIS DT, INGLESBY TV, HENDERSON DA et al.: Tularemia as a biological weapon. Medical and public health management. JAMA (2001) 285:2763-2773.
24. SANDSTROM G, LOFGREN S, TARNVIK A: A capsule-deficient mutant of Francisella tularensis LVS exhibits enhanced sensitivity to killing by serum but diminished sensitivity to killing by polymorphonuclear leukocytes. Infect. Immun. (1988) 56:1194-1202.
25. CONLAN JW, SJOSTEDT A, NORTH RJ: CD4+ and CD8+ T-cell-dependent and -independent host defence mechanisms can operate to control and resolve primary and secondary Francisella tularensis LVS infection in mice. Infect. Immun. (1994) 62:5603-5607.
26. FORTIER AH, GREEN SJ, POLSINELLI T et al.: Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol. Serol. (1994) 60:349-361.
27. GOLOVLIOV I, KUOPPA K, SJOSTEDT A, TARNVIK A, SANDSTROM G: Cytokine expression in the liver of mice infected with a highly virulent strain of Francisella tularensis. FEMS Immunol. Med. Microbiol. (1996) 13:239-244.
28. KROCA M, TARNVIK A, SJOSTEDT A: The proportion of circulating gamma delta T cells increases after the first week of onset of tularaemia and remains elevated for more than a year. Clin. Exp. Immunol. (2000) 120:280-284.
29. POQUET Y, KROCA M, HALARY F et al.: Expansion of V gamma 9V delta 2 T cells is triggered by Francisella tularensis-derived phosphoantigens in tularemia but not after tularemia vaccination. Infect. Immun. (1998) 66:2107-2114.
30. SJOSTEDT A, CONLAN JW, NORTH RJ: Neutrophils are critical for host defence against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defence against reinfection. Infect. Immun. (1994) 62:2779-2783.
31. COUNCILMAN WT, STRONG RP: Plague-like infections in rodents. Trans. Assoc. Am. Physicians (1921) 36:135-143.
32. FRANCIS E: Microscopic changes of tularemia in the tick Dermacentor andersoni and the bedbug Cimex lectularius. Public Health Rep. (1927) 42:2763-2772.
33. BUDDINGH GJ, WOMACK FC: Observations on the infection of chick embryos with Bacterium tularense and Pasteurella pestis. J. Exp. Med. (1941) 74:213-222.
34. SHEPARD CC: Nonacid-fast bacteria and HeLa cells: their uptake and subsequent intracellular growth. J. Bacteriol. (1959) 77:701-714.
35. ANTHONY LSD, BURKE RD, NANO FE: Growth of Francisella spp. in rodent macrophages. Infect. Immun. (1991) 59:3291-3296.
36. FORTIER AH, LEIBY DA, NARAYANAN RB et al.: Growth of Francisella tularensis LVS in macrophages: the acidic intracellular compartment provides essential iron required for growth. Infect. Immun. (1995) 63:1478-1483.
37. ABD H, JOHANSSON T, GOLOVLIOV I, SANDSTROM G, FORSMAN M: Survival and growth of Francisella tularensis in Acanthamoeba castellanii. Appl. Environ. Microbiol. (2003) 69:600-606.
38. LOFGREN S, TARNVIK A, THORE M, CARLSSON J: A wild and an attenuated strain of Francisella tularensis differ in susceptibility to hypochlorous acid - a possible explanation of their different handling by polymorphonuclear leukocytes. Infect. Immun. (1984) 43:730-734.
39. LOFGREN S, TARNVIK A, BLOOM GD, SJOBERG W: Phagocytosis and killing of Francisella tularensis by human polymorphonuclear leukocytes. Infect. Immun. (1983) 39:715-720.
40. REILLY TJ, BARON GS, NANO FE, KUHLENSCHMIDT MS: Characterization and sequencing of a respiratory burst-inhibiting acid phosphatase from Francisella tularensis. J. Biol. Chem. (1996) 271:10973-10983.
41. ERIKSSON S, LUCCHINI S, THOMPSON A, RHEN M, HINTON JCD: Unravelling the biology of macrophage infection by gene expression profiling of intracellular Salmonella enterica. Mol. Microbiol. (2003) 47:103-118.
42. TELEPNEV M, GOLOVLIOV I, GRUNDSTROM T, TARNVIK A, SJOSTEDT A: Francisella tularensis inhibits Toll-like receptor-mediated activation of intracellular signalling and secretion of TNF-alpha and IL-1 from murine macrophages. Cell Microbiol. (2003) 5:41-51.
43. GOLOVLIOV I, ERICSSON M, SANDSTROM G, TARNVIK A, SJOSTEDT A: Identification of proteins of Francisella tularensis induced during growth in macrophages and cloning of the gene encoding a prominently induced 23-kilodalton protein. Infect. Immun. (1997) 65:2183-2189.
44. KWAIK YA, EISENSTEIN BI, ENGELBERG NC: Phenotypic modification of Legionella pneumophila upon infection of macrophages. Infect. Immun. (1993) 61:1320-1329.
45. BARON GS, NANO FE: MglA and MglB are required for the intramacrophage growth of Francisella novicida. Mol. Microbiol. (1998) 29:247-259.
46. KARLSSON J, PRIOR RG, WILLIAMS K et al.: Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccine. Microbiol. Comp. Gen. (2000) 5:25-39.
47. ANTHONY LSD, COWLEY SC, MDLULI KE, NANO FE: Isolation of a Francisella tularensis mutant that is sensitive to serum and oxidative killing and is avirulent in mice: correlation with the loss of MinD homologue expression. FEMS Microbiol Lett. (1994) 124:157-166.
48. SJOSTEDT A, TARNVIK A, SANDSTROM G: Francisella tularensis: host-parasite interaction. FEMS Immunol. Med. Microbiol. (1996) 13:181-184.
49. POLLITZER R: History and incidence of tularemia in the Soviet Union. A review. The Institute of Contempory Russian Studies, New York, NY: Fordham University (1967).
50. EIGELSBACH HT, DOWNS CM: Prophylactic effectiveness of live and killed tularemia vaccines. I. J. Immunol. (1961) 87:415-425.
51. ELLIS J, OYSTON PCF, GREEN M, TITBALL RW: Tularemia. Clin. Microbiol. Rev. (2002) 15:631-646.
52. SASLAW S, EIGELSBACH HT, WILSON HE, PRIOR JA, CARHART S: Tularemia vaccine study. I. Intracutaneous challenge. Arch. Intern. Med. (1961) 107:689-701.
53. SASLAW S, EIGELSBACH HT, PRIOR JA, WILSON HE, CARHART S: Tularemia vaccine study. II. Respiratory challenge. Arch. Intern. Med. (1961) 107:702-714.
54. HORNICK RB, EIGELSBACH HT: Aerogenic immunization of man with live tularemia vaccine. Bacteriol. Rev. (1966) 30:532-538.
55. HORNICK RB, DAWKINS AT, EIGELSBACH HT, TULIS JJ: Oral tularemia vaccine in man. Antimicrob. Agent. Chemother. (1966) 6:11-14.
56. BENTLEY R: The shikimate pathway - a metabolic tree with many branches. Crit. Rev. Biochem. Mol. Biol. (1990) 25:307-384.
57. CHARLES I, DOUGAN G: Gene expression and the development of live enteric vaccines. Trends Biotechnol. (1990) 8:117-121.
58. DOUGAN G: The molecular basis for the virulence of bacterial pathogens - implications for oral vaccine development. Microbiology (1994) 140:215-224.
59. STOCKER BAD: Auxotrophic Salmonella typhi as live vaccine. Vaccine (1988) 6:141-145.
60. CERSINI A, SALVIA AM, BERNARDINI ML: Intracellular multiplication and virulence of Shigella flexnen auxotrophic mutants. Infect. Immun. (1998) 66:549-557.
61. SCOTT PV, MARKHAM JF, WHITHEAR KG: Safety and efficacy of two live Pasteurella multocida aroA mutant vaccines in chickens. Avian Dis. (1999) 43:83-88.
62. MARSDEN MJ, VAUGHAN LM, FITZPATRICK RM, FOSTER TJ, SECOMBES CJ: Potency testing of a live, genetically attenuated vaccine for salmonids. Vaccine (1998) 16:1087-1094.
63. STOCKER BAD, HOISETH SK, SMITH BP: Aromatic-dependent Salmonella sp as live vaccine in mice and calves. Dev. Biol. Stand. (1982) 53:47-54.
64. HOISETH SK, STOCKER BAD: Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature (1981) 291:238-239.
65. SMITH BP, REINAGUERRA M, HOISETH SK et al: Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am. J. Vet. Res. (1984) 45:59-66.
66. CRAWFORD RM, VANDEVERG L, YUAN L et al: Deletion of purE attenuates Brucella melitensis infection in mice. Infect. Immun. (1996) 64:2188-2192.
67. JACKSON M, PHALEN SW, LAGRANDERIE M et al.: Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine. Infect. Immun. (1999) 67:2867-2873.
68. IVANOVICS G, MARJAI E, DOBOZY A: The growth of purine mutants of Bacillus anthracis in the body of the mouse. J. Gen. Microbiol. (1968) 53:147-162.
69. BRUBAKER R: Interconversion of purine mononucleotides in Pasteurella pestis. Infect. Immun. (1970) 1:446-454.
70. MCFARLAND WC, STOCKER BAD: Effect of different purine auxotrophic mutations on mouse virulence of a Vipositive strain of Salmonella dublin and of 2 strains of Salmonella typhimurium. Microb. Pathog. (1987) 3:129-141.
71. O'CALLAGHAN D, MASKELL D, LIEW FY, EASMON CSF, DOUGAN G: Characterization of aromatic-dependent and purine-dependent Salmonella typhimurium - attenuation, persistence, and ability to induce protective immunity in Balb/C mice. Infect. Immun. (1988) 56:419-423.
72. HONDALUS MK, BARDAROV S, RUSSELL R et al.: Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis. Infect. Immun (2000) 68:2888-2898.
73. MCADAM RA, WEISBROD TR, MARTIN J et al.: In vivo growth characteristics of leucine and methionine auxotrophic mutants of Mycobacterium bovis BCG generated by transposon mutagenesis. Infect. Immun. (1995) 63:1004-1012.
74. ATKINS T, PRIOR RG, MACK K et al.: A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect. Immun. (2002) 70:5290-5294.
75. HOHMANN EL, OLETTA CA, KILLEEN KP, MILLER SI: phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. (1996) 173:1408-1414.
76. MCVEY DS, CHENGAPPA MM, MOSIER DE et al.: Immunogenicity of chi(4127) phoP-Salmonella enterica serovar Typhimurium in dogs. Vaccine (2002) 20:1618-1623.
77. ZHANG X, KELLY SM, BOLLEN W, CURTISS R: Protection and immune responses induced by attenuated Salmonella typhimurium UK-1 strains. Microb. Pathog. (1999) 26:121-130.
78. HASSAN JO, CURTISS R: Development and evaluation of an experimental vaccination program using a live avirulent Salmonella typhimurium strain to protect immunized chickens against challenge with homologous and heterologous Salmonella serotypes. Infect. Immun. (1994) 62:5519-5527.
79. FOSHAY L, HESSELBROCK WH, WITTENBERG HJ, RODENBERG AH: Vaccine prophylaxis against tularemia in man. Am. J. Public Health (1942) 32:1131-1145.
80. FOSHAY L: A comparative study of the treatment of tularemia with immune serum, hyperimmune serum and strepomycin. Am. J. Med. (1946):180-188.
81. CORIELL LL, KING EO, SMITH MG: Studies on Tularemia IV. Observations on tularemia in control and vaccinated monkeys. J. Immunol. (1948):183-202.
82. KADULL PJ, REAMES HR, CORIELL LL, FOSHAY L: Studies on tularemia. V. Immunisation of man. J. Immunol. (1950) 65:425-435.
83. FOSHAY L: Tularemia. Ann. Rev. Microbiol. (1950) 4:313-330.
84. FULOP M, MANCHEE R, TITBALL R: Role of lipopolysaccharide and a major outer-membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine (1995) 13:1220-1225.
85. FULOP M, MASTROENI P, GREEN M, TITBALL RW: Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine (2001) 19:4465-4472.
86. CONLAN JW, SHEN H, WEBB A, PERRY MB: Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine (2002) 20:3465-3471.
87. TARNVIK A: Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. (1989) 11:440-451.
88. SANDSTROM G, TARNVIK A, WOLF-WATZ H: Immunospecific T-lymphocyte stimulation by membrane proteins from Francisella tularensis. J. Clin. Microbiol. (1987) 25:641-644.
89. SURCEL HM, SARVAS M, HELANDER IM, HERVA E: Membrane proteins of Franceisella tularensis LVS differ in ability to induce proliferation of lymphocytes from tularemia-vaccinated individuals. Microb. Pathog. (1989) 7:411-419.
90. SJOSTEDT A, SANDSTROM G, TARNVIK A: Several membrane polypeptides of the live vaccine strain Francisella tularensis LVS stimulate T cells from naturally infected individuals. J. Clin Microbiol. (1990) 28:43-48.
91. BEVANGER L, MAELAND JA, NAESS AI: Competitive enzyme-immunoassay for antibodies to a 43,000-molecular-weight Francisella tularensis outer-membrane protein for the diagnosis of tularemia. J. Clin. Microbiol. (1989) 27:922-926.
92. GOLOVLIOV I, ERICSSON M, AKERBLOM L et al.: Adjuvanticity of iscoms incorporating a T-cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine (1995) 13:261-267.
93. SJOSTEDT A, SANDSTROM G, TARNVIK A: Humoral and cell-mediated immunity in mice to a 17-kilodalton lipoprotein of Francisella tularensis extressed by Salmonella typhimurium. Infect. Immun. (1992) 60:2855-2862.
94. COWLEY SC, GRAY CJ, NANO FE: Isolation and characterization of Francisella novicida mutants defective in lipopolysaccharide biosynthesis. FEMS Microbiol. Lett. (2000) 182:63-67.
95. HOOD AM: Virulence factors of Francisella tularensis. J. Hyg. (1977) 79:47-65.
96. LISSOLO L, QUENTIN-MILLET MJ: New strategies for identifying and developing novel vaccines; genome based discoveries. In: Fighting Infection in the 21st Century. Andrew PW, Oyston PCF, Smith GL, Stewart-Tull DE (Eds), Blackwell Science, Oxford, UK (2000):217-236.
97. PIZZA M, SCARLATO V, MASIGNANI V et al.: Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 287:1816-1820.
98. ROSS BC, CZAJKOWSKI L, HOCKING D et al: Identification of vaccine candidate antigens from a genomic analysis of Porphyromonas gingivalis. Vaccine (2001) 19:4135-4142.
99. ARIELN, ZVI A, GROSFELD H et al.: Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening. Infect. Immun. (2002) 70:6817-6827.
100. WIZEMANN TM, HEINRICHS JH, ADAMOU JE et al.: Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect. Immun. (2001) 69:1593-1598.
101. MONTIGIANI S, FALUGI F, SCARSELLI M et al.: Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect. Immun. (2002) 70:368-379.